- Home
- PCQ vs PROK Comparison
PCQ vs PROK Comparison
Compare PCQ & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCQ
- PROK
- Stock Information
- Founded
- PCQ 2001
- PROK 2015
- Country
- PCQ United States
- PROK United States
- Employees
- PCQ N/A
- PROK N/A
- Industry
- PCQ Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCQ Finance
- PROK Health Care
- Exchange
- PCQ Nasdaq
- PROK Nasdaq
- Market Cap
- PCQ 174.4M
- PROK 206.0M
- IPO Year
- PCQ N/A
- PROK N/A
- Fundamental
- Price
- PCQ $9.34
- PROK $1.50
- Analyst Decision
- PCQ
- PROK Buy
- Analyst Count
- PCQ 0
- PROK 5
- Target Price
- PCQ N/A
- PROK $4.50
- AVG Volume (30 Days)
- PCQ 69.6K
- PROK 344.0K
- Earning Date
- PCQ 01-01-0001
- PROK 03-21-2025
- Dividend Yield
- PCQ 4.63%
- PROK N/A
- EPS Growth
- PCQ N/A
- PROK N/A
- EPS
- PCQ N/A
- PROK N/A
- Revenue
- PCQ N/A
- PROK N/A
- Revenue This Year
- PCQ N/A
- PROK N/A
- Revenue Next Year
- PCQ N/A
- PROK N/A
- P/E Ratio
- PCQ N/A
- PROK N/A
- Revenue Growth
- PCQ N/A
- PROK N/A
- 52 Week Low
- PCQ $8.19
- PROK $1.34
- 52 Week High
- PCQ $10.50
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- PCQ 65.52
- PROK 41.47
- Support Level
- PCQ $9.04
- PROK $1.50
- Resistance Level
- PCQ $9.00
- PROK $1.67
- Average True Range (ATR)
- PCQ 0.07
- PROK 0.10
- MACD
- PCQ 0.03
- PROK -0.00
- Stochastic Oscillator
- PCQ 93.75
- PROK 10.71
About PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal and California income tax. The fund makes investments in different sectors such as healthcare, property, education, Natural Gas, and others.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.